HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ludwig Kiesel Selected Research

Syndecan-1 (Syndecan 1)

10/2022The heparan sulphate proteoglycan Syndecan-1 (CD138) regulates tumour progression in a 3D model of ductal carcinoma in situ of the breast.
1/2022Differential Impact of Membrane-Bound and Soluble Forms of the Prognostic Marker Syndecan-1 on the Invasiveness, Migration, Apoptosis, and Proliferation of Cervical Cancer Cells.
5/2021Syndecan-1 Promotes Angiogenesis in Triple-Negative Breast Cancer through the Prognostically Relevant Tissue Factor Pathway and Additional Angiogenic Routes.
5/2013Syndecan-1 modulates β-integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation.
3/2013Targeting of syndecan-1 by micro-ribonucleic acid miR-10b modulates invasiveness of endometriotic cells via dysregulation of the proteolytic milieu and interleukin-6 secretion.
1/2013Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling.
9/2012Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism.
2/2012Evaluation of placental syndecan-1 expression in early pregnancy as a predictive fetal factor for pregnancy outcome.
4/2009Role of the heparan sulfate proteoglycan syndecan-1 (CD138) in delayed-type hypersensitivity.
3/2009Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ludwig Kiesel Research Topics

Disease

39Breast Neoplasms (Breast Cancer)
10/2022 - 07/2003
30Neoplasms (Cancer)
05/2022 - 07/2003
11Endometriosis
03/2022 - 12/2003
9Triple Negative Breast Neoplasms
05/2021 - 01/2011
6Neoplasm Metastasis (Metastasis)
05/2022 - 04/2016
5Carcinogenesis
01/2021 - 04/2004
4Noninfiltrating Intraductal Carcinoma (DCIS)
10/2022 - 10/2004
4Uterine Cervical Neoplasms (Cancer of the Cervix)
02/2022 - 05/2021
4Carcinoma (Carcinomatosis)
01/2022 - 01/2006
3Ovarian Neoplasms (Ovarian Cancer)
12/2022 - 05/2021
3Inflammation (Inflammations)
05/2022 - 04/2009
3Cardiovascular Diseases (Cardiovascular Disease)
06/2021 - 05/2020
3Osteoporosis
06/2021 - 04/2016
3Endometrial Neoplasms (Endometrial Cancer)
11/2018 - 10/2011
3Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal)
01/2018 - 10/2007
3Leiomyoma (Uterine Fibroids)
07/2011 - 02/2009
2Dyslipidemias (Dyslipidemia)
05/2020 - 02/2009
2Psychological Sexual Dysfunctions (Sexual Arousal Disorder)
05/2020 - 11/2009
2Hyperplasia
02/2015 - 10/2007
2Infertility (Sterility)
07/2011 - 10/2007
2Obesity
12/2009 - 02/2009
2Ehlers-Danlos Syndrome (Syndrome, Ehlers-Danlos)
04/2008 - 07/2006
2Breast Diseases (Breast Disease)
10/2007 - 04/2004
1Serous Cystadenocarcinoma
05/2022
1Necrosis
03/2022
1Pain (Aches)
01/2022
1Urinary Incontinence
06/2021
1Chronic Disease (Chronic Diseases)
06/2021
1Urinary Tract Infections (Urinary Tract Infection)
06/2021
1Primary Ovarian Insufficiency
06/2021
1Atrophy
06/2021
1Dementia (Dementias)
06/2021

Drug/Important Bio-Agent (IBA)

12Syndecan-1 (Syndecan 1)IBA
10/2022 - 01/2006
10Hormones (Hormone)IBA
11/2021 - 12/2003
8Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)IBA
05/2022 - 04/2009
8Estrogens (Estrogen)FDA Link
06/2021 - 07/2003
7MicroRNAs (MicroRNA)IBA
10/2021 - 09/2012
7Progesterone Receptors (Progesterone Receptor)IBA
01/2021 - 07/2003
6Small Interfering RNA (siRNA)IBA
12/2022 - 09/2012
6Messenger RNA (mRNA)IBA
12/2022 - 04/2005
6Heparitin Sulfate (Heparan Sulfate)IBA
01/2021 - 04/2008
6Endothelins (Endothelin)IBA
08/2010 - 09/2003
5Cadherins (E-Cadherin)IBA
10/2022 - 01/2007
5Endothelin-1 (Endothelin 1)IBA
09/2010 - 09/2003
4Indicators and Reagents (Reagents)IBA
10/2021 - 07/2003
4Proteins (Proteins, Gene)FDA Link
01/2018 - 03/2005
3CytokinesIBA
05/2022 - 04/2009
3Biomarkers (Surrogate Marker)IBA
01/2022 - 07/2014
3EnzymesIBA
08/2020 - 04/2008
3Aromatase InhibitorsIBA
01/2018 - 06/2009
3IntegrinsIBA
01/2015 - 04/2009
3Endothelin A ReceptorIBA
09/2010 - 04/2005
3Estrogen ReceptorsIBA
06/2009 - 09/2003
3Endothelin B ReceptorIBA
04/2004 - 09/2003
2Proteoglycans (Proteoglycan)IBA
10/2022 - 04/2008
2Paclitaxel (Taxol)FDA LinkGeneric
05/2022 - 06/2010
2Syndecan-3IBA
05/2022 - 12/2009
2Peptide Hydrolases (Proteases)FDA Link
05/2022 - 12/2014
2RNA-Binding Proteins (RNA-Binding Protein)IBA
03/2022 - 03/2020
2Syndecan-4IBA
10/2021 - 01/2016
2CollagenIBA
01/2021 - 07/2006
2SulfotransferasesIBA
01/2021 - 01/2020
2Testosterone (Sustanon)FDA Link
05/2020 - 11/2009
2ErbB Receptors (EGF Receptor)IBA
02/2018 - 08/2010
2Phenobarbital (Luminal)FDA Link
01/2018 - 09/2012
2Anastrozole (Arimidex)FDA LinkGeneric
01/2018 - 09/2010
2Letrozole (Femara)FDA LinkGeneric
01/2018 - 02/2008
2Selective Estrogen Receptor Modulators (SERM)IBA
01/2018 - 06/2009
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
02/2015 - 04/2004
2AndrogensIBA
02/2015 - 01/2008
2ChemokinesIBA
01/2013 - 04/2009
2Fulvestrant (Faslodex)FDA Link
09/2010 - 06/2009
2Trastuzumab (Herceptin)FDA Link
08/2010 - 03/2006
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
06/2010 - 01/2006
2Estrogen Receptor alphaIBA
06/2009 - 10/2004
2Estrogen Receptor Modulators (Antiestrogen)IBA
06/2009 - 10/2004
2GlycosaminoglycansIBA
03/2009 - 04/2008
2Estradiol (Delestrogen)FDA LinkGeneric
04/2008 - 04/2005
2xylosylprotein 4-beta-galactosyltransferaseIBA
04/2008 - 07/2006
1Hyaluronic Acid (Hyaluronan)IBA
12/2022
1Hyaluronan SynthasesIBA
12/2022
1rho-Associated KinasesIBA
10/2022
1Extracellular Matrix ProteinsIBA
05/2022
1SyndecansIBA
05/2022
1EndometIBA
03/2022
1Cyclin-Dependent Kinase Inhibitor p21IBA
03/2022
1ResveratrolIBA
01/2022
1trans-sodium crocetinate (crocetin)IBA
01/2022
1Analgesics (Analgesic Drugs)IBA
01/2022
1LubricantsIBA
06/2021
1Thromboplastin (Tissue Factor)IBA
05/2021

Therapy/Procedure

27Therapeutics
02/2022 - 07/2003
13Drug Therapy (Chemotherapy)
05/2022 - 01/2006
3Palliative Care (Palliative Therapy)
02/2022 - 01/2011
3Radiotherapy
02/2022 - 11/2018
3Contraindications
05/2021 - 02/2009
3Neoadjuvant Therapy
07/2014 - 01/2006
2Brachytherapy
02/2022 - 02/2022
2Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
02/2022 - 02/2022
2Adjuvant Radiotherapy
11/2018 - 10/2018